Treatment of Pityriasis Rubra Pilaris with Adalimumab: A Case Report

Joshua R Kaminetsky; Eric J Feit; Jonathan P Ungar

doi:10.25251/2.5.9

Joshua R Kaminetsky

Albert Einstein College of Medicine, Bronx, NY Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, NY

Eric J Feit

Albert Einstein College of Medicine, Bronx, NY Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, NY

Jonathan P Ungar

Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, NY

Keywords

Abstract

Pityriasis Rubra Pilaris (PRP) is a rare inflammatory dermatosis of unknown etiology and variable presentation. Common clinical features include hyperkeratotic follicular papules, palmoplantar hyperkeratosis and well-demarcated red-orange scaly plaques interspersed with islands of unaffected skin. A limited body of anecdotal evidence predominantly supports the use of systemic retinoids and/or methotrexate in treating the disease. In a subset of these patients, there has been a documented role for biologic tumor necrosis factor (TNF) inhibitors, especially in patients who have failed retinoid or antimetabolite therapy. We present a case of a woman whose PRP responded favorably to adalimumab, highlighting the role of TNF inhibitors and the need for their continued exploration in the treatment of PRP.

References

Borok M, Lowe NJ. Pityriasis rubra pilaris. Further observations of systemic retinoid therapy. J Am Acad Dermatol. 1990;22(5 Pt 1):792.

Chapalain V, Beylot-Barry M, Doutre MS, Beylot C. Treatment of pityriasis rubra pilaris: a retrospective study of 14 patients. J Dermatolog Treat. 1999;10:113-117.

Zhang YH, Zhou Y, Ball N, Su MW, Xu JH, Zheng ZZ. Type I pityriasis rubra pilaris: upregulation of tumor necrosis factor alpha and response to adalimumab therapy. J Cutan Med Surg. 2010 Jul;14(4):185-8.

Seckin D, Tula E, Ergun T. Successful use of etanercept in type I pityriasis rubra pilaris. Br J Dermatol 2008; 158: 642-4.  

Garcovich S, Di Giampetruzzi AR, Antonelli G, Garcovich A, Didona B. Treatment of refractory adult-onset pityriasis rubra pilaris with TNF-alpha antagonists: a case series. J Eur Acad Dermatol Venereol. 2010;24(8):881.

Walling HW, Swick BL. Pityriasis rubra pilaris responding rapidly to adalimumab. Arch Dermatol. 2009 Jan;145(1):99-101.1

O'Kane D, Devereux CE, Walsh MY, Hoey SE. Rapid and sustained remission of pityriasis rubra pilaris with adalimumab treatment. Clin Exp Dermatol. 2010;35(4):e155.

Schreml S, Zeller V, Babilas P, Karrer S, Landthaler M, Szeimies RM. Pityriasis rubra pilaris successfully treated with adalimumab. Clin Exp Dermatol. 2010 Oct;35(7):792-3.

Wassef C, Lombardi A, Rao BK. Adalimumab for the Treatment of Pityriasis Rubra Pilaris: A Case Reprot. Cutis. 2012 November;90(5):244-247.

Bravo E, Carrion L, Paucar, SM, Mendoza R, Rivera C. Successful treatment of pityriasis rubra pilaris with adalimumab. Dermatol Online Journal. 2014 Jan;20(4):11.

Petrof G, Almaani N, Archer C, Griffiths W, Smith C. A systematic review of the literature on the treatment of pityriasis rubra pilaris type 1 with TNF-antagonists. JEADV 2013; 27: 131-5.  

Kouklakis G, Efremidou E, Pitiakoudis M, et al. Development of primary malignant melanoma during treatment with a TNF-α antagonist for severe Crohn’s disease: a case report and review of the hypothetical association between TNF-α blockers and cancer. Drug Des Devel Ther. 2013.7: 195-9

Full Article PDF

Published

Sep 7, 2018

DOI https://doi.org/10.25251/2.5.9

How to Cite

Kaminetsky, J. R., Feit, E. J., & Ungar, J. P. (2018). Treatment of Pityriasis Rubra Pilaris with Adalimumab: A Case Report. SKIN The Journal of Cutaneous Medicine, 2(5). https://doi.org/10.25251/2.5.9

Issue

Vol. 2 No. 5 (2018)

Section

Brief Articles

This work is licensed under a Creative Commons Attribution 4.0 International License.

All authors retain copyright in their articles. All articles published open access allowing for immediate free access to the work and permitting any user to read, download, copy, distribute, print, search, or link to the full texts of articles, crawl them for indexing, pass them as data to software or use them for any other lawful purpose. Permitted reuse is defined by the following user license:

Creative Commons Attribution (CC BY): lets others distribute and copy the article, to create extracts, abstracts, and other revised versions, adaptations or derivative works of or from an article (such as a translation), to include in a collective work (such as an anthology), to text or data mine the article, even for commercial purposes, as long as they credit the author(s), do not represent the author as endorsing their adaptation of the article, and do not modify the article in such a way as to damage the author's honor or reputation.

Authors retain copyright in their work and license the publisher to publish the content. The publisher is the National Society for Cutaneous Medicine, with production and publishing support provided by OJS, Open Journal Systems,see https://pkp.sfu.ca/ojs/.

Prior to January 2022, authors transferred copyright to the National Society for Cutaneous Medicine. However, all articles are freely available to anyone in the world. There are no subscription fees, page charges, or article processing charges.

Author Biographies

Joshua R Kaminetsky, Albert Einstein College of Medicine, Bronx, NY Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, NY

Medical student, Department of Dermatology

Eric J Feit, Albert Einstein College of Medicine, Bronx, NY Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, NY

Medical student, Department of Dermatology

Jonathan P Ungar, Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, NY

Instructor, Department of Dermatology

Treatment of Pityriasis Rubra Pilaris with Adalimumab: A Case Report

Keywords

Abstract

References

Joshua R Kaminetsky, Albert Einstein College of Medicine, Bronx, NY Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, NY

Eric J Feit, Albert Einstein College of Medicine, Bronx, NY Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, NY

Jonathan P Ungar, Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, NY

Similar Articles

Most read articles by the same author(s)

Similar Articles

Deucravacitinib, an Oral, Selective Tyrosine Kinase 2 (TYK2) Inhibitor, Compared With Placebo and Apremilast in Moderate to Severe Psoriasis: Integrated Laboratory Parameter Results From the Phase 3 POETYK PSO-1 and POETYK PSO-2 Trials

Deucravacitinib, an Oral, Selective Tyrosine Kinase 2 (TYK2) Inhibitor, Versus Placebo and Apremilast in Moderate to Severe Plaque Psoriasis: Onset of Action in the Phase 3 POETYK PSO-1 and POETYK PSO-2 Trials

Deucravacitinib, an oral, selective tyrosine kinase 2 inhibitor, versus placebo and apremilast in moderate to severe plaque psoriasis: analysis of body surface area involvement in the phase 3 POETYK PSO-1 and PSO-2 trials

Optimizing the treatment sequence: the cumulative clinical benefit of treatment initiation with deucravacitinib versus apremilast over 52 weeks in patients with moderate to severe plaque psoriasis from the POETYK PSO-1 trial

Deucravacitinib, an Oral, Selective Tyrosine Kinase 2 (TYK2) Inhibitor, Versus Placebo and Apremilast in Moderate to Severe Plaque Psoriasis: Efficacy Analysis by Baseline Disease Characteristics From the Phase 3 POETYK PSO-1 and PSO-2 Trials

Main Article Content

Keywords

Abstract

References

Article Sidebar

Article Details

Joshua R Kaminetsky, Albert Einstein College of Medicine, Bronx, NY Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, NY

Eric J Feit, Albert Einstein College of Medicine, Bronx, NY Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, NY

Jonathan P Ungar, Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, NY

Similar Articles

Most read articles by the same author(s)